Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-08-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于2023年度为子公司提供担保的进展公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the progress of guarantees provided by Shenzhen BGI Genomics Co., Ltd. for its subsidiary Qingdao Qingxi BGI Genomics Co., Ltd. It includes specifics about the guarantee amount, the financing loan contract, the guarantee contract, financial data of the subsidiary, and compliance with regulatory requirements. The document is not a financial report, earnings release, or management discussion but rather a regulatory announcement about guarantees and financing arrangements. It does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update directly, as it focuses on guarantee progress and related contracts. Given the nature of the content and the regulatory disclosure style, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is 3310 characters, which is relatively short and typical for an announcement rather than a full report.
2023-08-01 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司二〇二三年第二次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of Shenzhen BGI Genomics Co., Ltd.'s 2023 second extraordinary general meeting of shareholders. It details the legal compliance of the meeting's call, attendance, and voting process according to relevant laws and company rules. The document does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of voting results but a legal opinion on the meeting's procedural legality. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and legal opinion on the shareholder meeting and its voting outcomes.
2023-07-20 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the "2023 Second Extraordinary General Meeting of Shareholders" of Shenzhen BGI Genomics Co., Ltd. It details the meeting date, voting methods, attendance, agenda items, voting results, and legal opinions confirming the meeting's legality. There is no financial data, earnings information, or detailed report content. The document is an official announcement of the voting results and resolutions passed at a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2305 characters), consistent with a voting results announcement rather than a full report or presentation.
2023-07-20 Chinese
关于召开2023年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2023 second extraordinary general meeting of shareholders for Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on, registration details, and attachments such as proxy forms and voting instructions. There is no financial data, earnings information, or report content. The document serves as a notice or announcement to shareholders about the meeting and voting process rather than the results or materials of the meeting itself. Therefore, it fits the category of a Declaration of Voting Results & Voting Rights Announcements (DVA) or a Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than solicitation materials or voting results, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is 4625 characters, which is sufficient for a detailed proxy statement. Hence, the classification is PSI with high confidence.
2023-07-17 Chinese
关于控股股东部分股份解除质押及再质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from Shenzhen BGI Genomics Co., Ltd. regarding the partial release and re-pledging of shares by its controlling shareholder. It details the number of shares involved, pledge dates, pledgees, and the impact on shareholding and financing. There is no financial statement, earnings data, or management discussion. The document is a regulatory disclosure about share pledge transactions by major shareholders, which fits the category of Major Shareholding Notification (MRQ). The document length is 2647 characters, which is relatively short and focused on shareholding changes rather than a full report or announcement of a report publication. Therefore, the appropriate classification is MRQ with high confidence.
2023-07-13 Chinese
关于补选第三届董事会独立董事及专门委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the election of a new independent director and committee member to the company's board. It details the resignation of a previous independent director and the nomination and qualifications of the new candidate. The content focuses on board composition changes and governance matters, without financial data or report publication. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-06-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.